Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714687 · ClinicalTrials.gov registry record · NA
Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)
A NA study of Recurrent Acute Rhinosinusitis, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
- 5
- Study locations
NCT01714687: Completed NA study of Recurrent Acute Rhinosinusitis, sponsored by Integra LifeSciences Corporation.
NCT01714687 is a NA study of Recurrent Acute Rhinosinusitis that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 59 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714687, a NA study of Recurrent Acute Rhinosinusitis, has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
- 5
- Study locations
Study Summary
This post-market study aims to compare health outcomes for Recurrent Acute Rhinosinusitis (RARS) patients treated with balloon sinus dilation (BSD) versus medical management alone.
Primary Outcome
The Chronic Sinusitis Survey (CSS) is a 6 question, duration-based survey to evaluate surgical outcomes for CRS patients. The CSS asks three questions about symptoms and three questions about medication usage and yields a symptom subscore, a medication subscore, and a total score. Scale values include "0 Weeks" (minimum), "1-2 Weeks", "3-4 Weeks", "5-6 Weeks", and "7-8 Weeks" (maximum). The severity of symptoms is scored 0 (none) to 4 (severe), and a total score is calculated from 0 (worst) to
Conditions Studied
Interventions
- DEVICE balloon sinus dilation
- OTHER medical therapy
Study Locations (5)
Texas
- - Dallas
- - McKinney
Alabama
- - Birmingham
Georgia
- - Atlanta
Nevada
- - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2012-10-01 |
| Est. Completion | 2016-04-01 |
| Phase | NA |
What the finished NCT01714687 record still lists
NCT01714687 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Recurrent Acute Rhinosinusitis appearing as the primary indexed condition, and to 2 interventions - of which balloon sinus dilation is the first listed.
NCT01714687 lists 5 locations in 4 states (Texas, Alabama, Georgia).
Frequently Asked Questions
What is clinical trial NCT01714687 about?
NCT01714687 is a clinical study titled "Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)". This post-market study aims to compare health outcomes for Recurrent Acute Rhinosinusitis (RARS) patients treated with balloon sinus dilation (BSD) versus medical management alone.
What is the current status of trial NCT01714687?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2012-10-01. Estimated completion is 2016-04-01.
What conditions does trial NCT01714687 study?
This clinical trial studies the following conditions: Recurrent Acute Rhinosinusitis.
What interventions are being tested in trial NCT01714687?
The interventions under investigation include: balloon sinus dilation (DEVICE), medical therapy (OTHER).
Who is sponsoring clinical trial NCT01714687?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01714687 being conducted?
This trial has 5 study locations across Alabama, Georgia, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01714687's enrollment target sits among peer trials
59 1256th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI